Table 2:
The combination of I-BET 762 and the rexinoid LG100268 for prevention of lung carcinogenesis
| Control | IBET 762 40 mg/kg diet | LG100268 40 mg/kg diet | I-BET762+LG268 40 mg each drug/kg diet | |
|---|---|---|---|---|
| Inflated lungs: | ||||
| # of mice/group | 24 | 12 | 12 | 12 |
| # of tumors/group | 188 | 60 | 62 | 57 |
| # of tumors/lung (% control) | 7.8±0.5 (100%) | 5.0±0.5* (63.8%) | 5.2±0.6*(66%) | 4.8±0.7* (60.6%) |
| # of tumors < 0.5 mm (% of total tumors) | 5 (2.7%) | 7* ( 11.7%) | 9** (14.5%) | 13** (22.8%) |
| # of tumors > 1 mm (% of total tumors) | 21 (11.2%) | 1* (1.7%) | 6 (9.7%) | 1 (1.8%) |
| Slides: | ||||
| # of slides/group | 48 | 24 | 24 | 24 |
| # of tumors/group | 92 | 22 | 39 | 19 |
| Average # of tumors/slide (% control) | 1.92±0.25 (100%) | 0.92±0.15* (47.8%) | 1.63±0.32 (84.8%) | 0.79±2* (41.3%) |
| Average Tumor Size, mm3 (% control) | 0.24±0.09 (100%) | 0.10±0.02* (39.8%) | 0.11±0.02* (45.8%) | 0.10±0.03* (42.5%) |
| Average Tumor Burden, mm3 (% control) | 0.47±0.19 (100%) | 0.09±0.02* (19.1%) | 0.18±0.04 (38.8%) | 0.08±0.03* (17.5%) |
| Histopathology: | ||||
| Total # LL Grade (% of total tumors) | 4 (4%) | 1 (4%) | 1 (3%) | 3 (16%) |
| Total # LH/HL Grade (% of total tumors) | 53 (58%) | 16 (73%) | 22 (56%) | 12 (63%) |
| Total # HH Grade (% of total tumors) | 35 (38%) | 5 (23%) | 16 (41%) | 4 (21%) |
Note: The same model was used as Table 1, but a lower concentration of I-BET 762 and a potent rexinoid (LG100268) were tested. The tumor number, size and histopathology were again assessed in a blinded fashion by two independent investigators. Results are shown as mean±SEM.
*,
p < 0.05 vs. control
**,
p < 0.001 vs. control.